Drug intelligence / Profile preview

GCA2011

Development stage: Preclinical
Lead developer: Guangzhou Green Cross Pharmaceutical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

GCA2011 is an investigational anti-infective agent currently under development by Guangzhou Green Cross Pharmaceutical. It is classified as a new chemical entity (NCE) and is being advanced in an innovative lipid microsphere formulation, which is also referred to by the code GCF2024. This formulation technology is a core platform for the developer, aimed at enhancing the delivery and efficacy of the active compound. As of early 2024, GCA2011 is in the IND-enabling (preclinical) stage, with plans to enter clinical trials for the treatment of various infections. Specific details regarding its molecular target and mechanism of action remain proprietary.

Beyond the preview

Go deeper on GCA2011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCA2011.

Explore the full profile